Israel’s D-Pharm has announced successful interim results in the Phase IIa clinical trial of its drug THR-18 taken in conjunction with tissue plasminogen activator (tPA) for the treatment of cerebral stroke. D-Pharm’s share price rose 117%, despite the trials taking place in the Ukraine.
http://www.globes.co.il/en/article-d-pharm-doubles-on-good-interim-stroke-study-results-1000921631